Mattsson N, Groot C, Jansen WJ, Landau SM, Villemagne VL, Engelborghs S, Mintun MM, Lleo A, Molinuevo JL, Jagust WJ, Frisoni GB, Ivanoiu A, Chetelat G, De Oliveira CR, Rodrigue KM, Kornhuber J, Wallin A, Klimkowicz-Mrowiec A, Kandimalla R, Popp J, Aalten PP, Aarsland D, Alcolea D, Almdahl IS, Baldeiras I, Van Buchem MA, Cavedo E, Chen K, Cohen AD, Foerster S, Fortea J, Frederiksen KS, Freund-Levi Y, Gill KD, Gkatzima O, Grimmer T, Hampel H, Herukka SK, Johannsen P, Van Laere K, De Leon MJ, Maier W, Marcusson J, Meulenbroek O, Mollergard HM, Morris JC, Mroczko B, Nordlund A, Prabhakar S, Peters O, Rami L, Rodriguez-Rodriguez E, Roe CM, Ruther E, Santana I, Schroder J, Seo SW, Soininen H, Spiru L, Stomrud E, Struyfs H, Teunissen CE, Verhey FRJ, Vos SJB, Van Doorn LJCVW, Waldemar G, Wallin AK, Wiltfang J, Vandenberghe R, Brooks DJ, Fladby T, Rowe CC, Drzezga A, Verbeek MM, Sarazin M, Wolk DA, Fleisher AS, Klunk WE, Na DL, Sanchez-Juan P, Lee DY, Nordberg A, Tsolaki M, Camus V, Rinne JO, Fagan AM, Zetterberg H, Blennow K, Rabinovici GD, Hansson O, Van Berckel BNM, Van Der Flier WM, Scheltens P, Visser PJ, Ossenkoppele R (2018)
Publication Type: Journal article
Publication year: 2018
Book Volume: 14
Pages Range: 913-924
Journal Issue: 7
DOI: 10.1016/j.jalz.2018.02.009
Apolipoprotein E (APOE) ?4 is the major genetic risk factor for Alzheimer's disease (AD), but its prevalence is unclear because earlier studies did not require biomarker evidence of amyloid ? (A?) pathology.We included 3451 A?+ subjects (853 AD-type dementia, 1810 mild cognitive impairment, and 788 cognitively normal). Generalized estimating equation models were used to assess APOE ?4 prevalence in relation to age, sex, education, and geographical location.The APOE ?4 prevalence was 66% in AD-type dementia, 64% in mild cognitive impairment, and 51% in cognitively normal, and it decreased with advancing age in A?+ cognitively normal and A?+ mild cognitive impairment (P < .05) but not in A?+ AD dementia (P = .66). The prevalence was highest in Northern Europe but did not vary by sex or education.The APOE ?4 prevalence in AD was higher than that in previous studies, which did not require presence of A? pathology. Furthermore, our results highlight disease heterogeneity related to age and geographical location.
APA:
Mattsson, N., Groot, C., Jansen, W.J., Landau, S.M., Villemagne, V.L., Engelborghs, S.,... Ossenkoppele, R. (2018). Prevalence of the apolipoprotein E ?4 allele in amyloid ? positive subjects across the spectrum of Alzheimer's disease. Alzheimers & Dementia, 14(7), 913-924. https://doi.org/10.1016/j.jalz.2018.02.009
MLA:
Mattsson, Niklas, et al. "Prevalence of the apolipoprotein E ?4 allele in amyloid ? positive subjects across the spectrum of Alzheimer's disease." Alzheimers & Dementia 14.7 (2018): 913-924.
BibTeX: Download